非小细胞肺癌组织LRP和p53表达及其与新辅助化疗关系的研究

Correlation among expressions of LRP,p53 protein and neoadjuvant chemotherapy response in non-small cell lung cancer

目的:了解非小细胞肺癌(NSCLC)患者LRP和p53的表达与含铂方案新辅助化疗的疗效以及预后之间的关系。方法:通过免疫组化方法研究43例Ⅲ期NSCLC化疗前后肺癌标本LRP和p53的表达,并分析上述指标的表达与新辅助化疗疗效以及生存期的关系。结果:在化疗前后的成对标本中,化疗后肺癌标本LRP和p53的表达[LRP为74.42%(32/43),p53为72.09%(31/43)],明显高于化疗前[LRP为46.51%(20/43),p53为48.84%(21/43)]。LRP阳性组化疗有效率为40%(8/20),LRP阴性组73.91%(17/23),LRP表达与化疗有效率呈负相关,P=0.033。p53阳性组化疗有效率76.19%(16/21),p53阴性组40.91%(9/22),p53表达与化疗有效率正相关,P=0.031。结论:Ⅲ期NSCLC化疗前LRP和p53表达有助预测含铂方案新辅助化疗的疗效。

OBJECTIVE： To understand the correlation among the expressions of lung resistance-related protein（LRP）, p53 protein and the response to platinum-based neoadjuvant chemotherapy in patients with non-small cell lung cancer（NSCLC）. METHODS： Pre- and post-chemotherapy immunohistochemical studies of lung cancer specimens were performed on 43 patients with stage Ⅲ NSCLC. The data on response rates were analyzed according to the expressions of LRP and P53. RESULTS： In paired samples before and after chemotherapy specimens, the expressions of LRP and p53 were significantly higher in post-chemotherapy samples [LRP 74.42% （32/43）, p53 72.09% （31/43）3 than those pre-chemotherapy [LRP 46.51% （20/43）, p53 48.84% （21/43）3. LRP expression significantly correlated inversely with the response to chemotherapy [response rates, 40%（8/20） for LRP-positive and 73. 91% （17/23） for LRP-negative], P= 0. 033. p53 expression correlated significantly with the response to chemotherapy [response rates, 76. 19% （16/21） for p53-positive and 40. 91% （9/22） for p53-negative, P=0. 031]. CONCLUSION： These findings indicate that the expressions of LRP and p53 may be useful to predict platinum-based neoadjuvant chemotherapy response in stage Ⅲ NSCLC.